Detalles de la búsqueda
1.
Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach.
J Transl Med
; 21(1): 257, 2023 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055772
2.
Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.
Histopathology
; 74(6): 817-828, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30589949
3.
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
Mod Pathol
; 30(12): 1666-1676, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28776578
4.
Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.
Nat Commun
; 15(1): 3014, 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38589406
5.
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies.
Oncoimmunology
; 12(1): 2261248, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37808404
6.
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.
J Immunother Cancer
; 11(10)2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37865395
7.
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.
Clin Cancer Res
; 29(1): 154-164, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36166093
8.
Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma.
Front Mol Biosci
; 9: 810858, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35664673
9.
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
J Immunother Cancer
; 10(9)2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096531
10.
Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis.
JCI Insight
; 7(21)2022 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36173679
11.
Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.
Cancers (Basel)
; 13(13)2021 Jun 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34202352
12.
Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients.
Oncoimmunology
; 9(1): 1659093, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32002281
13.
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
Clin Cancer Res
; 26(2): 487-504, 2020 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31636098
14.
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.
Clin Cancer Res
; 25(5): 1557-1563, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30409824
15.
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Cancer Cell
; 35(2): 238-255.e6, 2019 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30753825
16.
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Clin Cancer Res
; 24(6): 1260-1270, 2018 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29127120
Resultados
1 -
16
de 16
1
Próxima >
>>